poisar

Stock

Imunon, Inc. IMNN

$1.61+1.90%

Overview

IMNN market data

Price History

IMNN price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.58
Diluted earnings per share over the trailing twelve months.
Beta
2.02
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-6,901.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.47 – $7.21
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $6.8M · P/B 1.66 · P/S 13.08.

Company News

10 captured
8-K filing — Imunon, Inc. (IMNN)SEC EDGAR · Aug 11, 2026, 9:00 PM
Imunon Q2 EPS $(0.54) Beats $(0.93) EstimateBenzinga · Aug 11, 2026, 12:02 PM
12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · Aug 7, 2026, 9:05 PM
IMUNON Announces Its Phase 3 OVATION 3 Trial Of IMNN-001 In Patients With Ovarian Cancer Has Observed Rapid Site Activation And Above-Forecast Enrollment RateBenzinga · Jul 30, 2026, 1:01 PM
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer StudyBenzinga · Jul 30, 2026, 12:29 PM
EXCLUSIVE: Imunon Says Enrollment Momentum for Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer Exceeds Expectations; Projects Enrollment to Complete in Q2 of 2029Benzinga · Jul 30, 2026, 12:29 PM
IMUNON To Present New Data On IMNN-001, DNA-Based Interleukin-12 Immunotherapy For Advanced Ovarian Cancer, At Inaugural AACR Conference On Drug Discovery And DevelopmentBenzinga · Jul 23, 2026, 1:27 PM
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer PatientsBenzinga · Jul 21, 2026, 12:30 PM
EXCLUSIVE: Imunon Says Phase 2 IMNN-001 Data Showed Lower MRD, Higher ctDNA Clearance And Favorable Safety In Frontline Ovarian Cancer; Preliminary Data Reinforces Immunotherapy’s Potential For Success In Currently Recruiting Phase 3 OVATION 3 StudyBenzinga · Jul 21, 2026, 12:30 PM
Imunon Says Jeffrey Church To Retire As Interim CFO Effective July 1, 2026; Appoints Josh Blacher As Interim CFO Effective July 1, 2026Benzinga · Jun 30, 2026, 8:50 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock